Aim: Long-acting injectable (LAI)antipsychotics are often used in psychosis to assist with medication compliance and relapse prevention, although the weight gain and metabolic effects in young people are yet to be examined. This study examined the long-term effects of aripiprazole and paliperidone in LAI formulation on weight gain and metabolic parameters in young people with early episode psychosis.Methods: Weight gain and other metabolic effects of aripiprazole and paliperidone in LAI formulation were examined in 59 young people with early episode psychosis over a 12-month period. Changes in outcome measurements were examined at baseline and 3 monthly intervals. Results:The results showed that both aripiprazole and paliperidone were associated with time-dependent increases in weight. At 12 months, weight increased by an average of 7% (6 kg) with both aripiprazole and paliperidone relative to the baseline, and the percentage of overweight or obese people increased from 33% to 60%.There was no advantage of aripiprazole compared to paliperidone with regards to weight change, although aripiprazole was associated with lower triglycerides and prolactin levels.Conclusions: Both LAI medications were associated with substantial weight increases over time. These results build on emerging evidence showing that aripiprazole is not weight neutral in young people. Our recommendation is that weight-management programs should be offered from the start of medication initiation.adolescents, Second generation antipsychotic medication, weight gain, youth mental health | INTRODUCTIONSecond generation antipsychotic medications can assist in the treatment of early psychosis (Galletly et al., 2016). Because of growing concerns about side-effects however (Foley et al., 2013), it can be difficult for clinicians to choose which antipsychotic agent to prescribe.Another complication is the paucity of data about long-acting injectable (LAI) antipsychotic medications that are used to assist with medication compliance. In particular, the weight gain and metabolic effects of two newer LAI antipsychotics, aripiprazole and paliperidone, in young people with early psychosis are yet to be examined. For confidence to grow regarding the safety and tolerability of these LAI in young people, it is important to further examine any potential longterm adverse health effects.

Objective: Aripiprazole is often prescribed to young people, although there remain unanswered questions about its effects on weight gain. This study undertook a meta-analysis of weight gain occurring in young people with early psychosis who were prescribed aripiprazole. Method: A systematic search was conducted for studies reporting on aripiprazole and weight change in young people with a psychotic disorder. A meta-analysis integrated the data into an estimate of effect size. Results: Eleven studies met the inclusion criteria amounting to 886 participants (mean age 18 years). The results showed significant weight gain averaging 2.7 kg. These increases were associated with a longer duration of exposure to aripiprazole but not a higher dosage. Conclusions: The results highlight the importance of regular patient monitoring and the early implementation of interventions to manage antipsychotic-related weight gain.

No abstract

Background: Long-acting injectable (LAI) antipsychotics are increasingly being prescribed to young people diagnosed with psychosis 1 and can assist with medication compliance 2 . It is often postulated that aripiprazole has the least impact on weight gain and metabolic effects relative to other antipsychotics 3 . However, studies in young people are rare, and head to head comparisons against other LAIs such as paliperidone are lacking. Aims: To examine long-term changes in weight and metabolic side effects of aripiprazole and paliperidone in LAI formulation in young people being treated in a community headspace Youth Early Psychosis Program, Perth Australia. Methods: A physical health nurse conducted regular metabolic screening. Weight, BMI and blood pressure were taken monthly during administration of the depot. Metabolic parameters were taken at baseline, and then every 3 months for 12 months. 59 Young people Participants 33 young people on aripiprazole, and 26 on paliperidone: No baseline group differences in age (mean = 21.2 years, SD = 2.1); clinical severity (mean BPRS score = 40.2, SD = 10.8) or total duration on the current LAI (mean = 381 days, SD = 255). Results * Both groups showed significant time-dependent increases in BMI, weight and waist circumference (p < 0.001) * At 12 months, patients on aripiprazole had significantly greater waist circumference (20 cm vs 5 cm, p < 0.01) and weight gain since baseline (10.1% vs 5.3%).* Aripiprazole was also associated with lower triglycerides and prolactin levels compared to paliperidone (p < 0.001).

Transactional analysis is a unique technique of behaviour modification through which undesirable behaviour can be turned into affirmative and constructive behaviour. The present study was aimed to analyse transactions among early adolescents. The study sample comprised of 240 early adolescents (120 girls and 120 boys) from Government schools of Deesa City. Transactional pattern of girls was found to be better as compared to boys but statistically they were of same order. Reactive style was most preferred where as task managing was least preferred by total respondents. Task managing, adaptive and creative style was preferred by girls whereas boys favoured nurturing, regulating and reactive styles. Boys and girls differ significantly for reactive and creative style. Education, type of school and annual income were significant determinants of TA. HIND ARTS ACADEMY Received: